Ignite Creation Date:
2024-05-05 @ 11:24 PM
Last Modification Date:
2024-10-26 @ 10:33 AM
Study NCT ID:
NCT01328249
Status:
COMPLETED
Last Update Posted:
2019-08-20
First Post:
2011-03-22
Brief Title:
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Organization Data
Organization:
Eisai Inc
Class:
INDUSTRY
Study ID:
E7389-A001-210
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eisai Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None